Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Cronkhite-Canada syndrome (CCS) is a rare gastrointestinal (GI) polyposis syndrome characterized by the association of non-hereditary GI polyposis with the cutaneous triad of alopecia, nail changes and hyperpigmentation.
Features include: Protein-losing enteropathy, Alopecia, Malabsorption, and Nail dysplasia and 22 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 6 | Malabsorption, Anorexia, Diarrhea |
Skin |
Biomarker and diagnostic research for Cronkhite-Canada syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Cronkhite-Canada syndrome.
138 publications have been identified in PubMed for Cronkhite-Canada syndrome. Research spans Review / Meta-Analysis (48%), Case Report / Case Series (23%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 66 | 48% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Cronkhite-Canada syndrome
4
Alopecia, Nail dysplasia, Hyperpigmentation of the skin |
Eyes | 1 | Cataract |
Blood and immune system | 1 | Low red blood cell count (anemia) |
Muscles | 1 | Muscle weakness |
Brain and nerves | 1 | Paresthesia |
Arms and legs | 1 | Clubbing of fingers |
Growth and development | 1 | Cachexia |
32 |
23% |
Clinical study results | 18 | 13% |
Laboratory research | 12 | 9% |
Disease patterns and progression | 6 | 4% |
Other research | 2 | 1% |
Testing and diagnosis research | 2 | 1% |
Imazu Y (2026). [PMID: 41762677](https://pubmed.ncbi.nlm.nih.gov/41762677/). *Digestion*. [Review / Meta-Analysis]
Wang Y (2026). [PMID: 42136875](https://pubmed.ncbi.nlm.nih.gov/42136875/). *Front Med (Lausanne)*. [Case Report / Case Series]
Asim M (2026). [PMID: 41691291](https://pubmed.ncbi.nlm.nih.gov/41691291/). *J Med Case Rep*. [Case Report / Case Series]
Xu Y (2026). [PMID: 41435605](https://pubmed.ncbi.nlm.nih.gov/41435605/). *Phytomedicine*. [Basic Science / Preclinical]
Fujihara D (2026). [PMID: 42049422](https://pubmed.ncbi.nlm.nih.gov/42049422/). *In Vivo*. [Basic Science / Preclinical]
Nasirishargh A (2026). [PMID: 42010853](https://pubmed.ncbi.nlm.nih.gov/42010853/). *Am J Case Rep*. [Case Report / Case Series]
Aboobacker S (2026). [PMID: 30485005](https://pubmed.ncbi.nlm.nih.gov/30485005/). *Unknown Journal*. [Case Report / Case Series]
Zhao ZZ (2026). [PMID: 42116590](https://pubmed.ncbi.nlm.nih.gov/42116590/). *Med Sci Monit*. [Review / Meta-Analysis]
Tsutsumi S (2026). [PMID: 41773736](https://pubmed.ncbi.nlm.nih.gov/41773736/). *Am J Gastroenterol*. [Case Report / Case Series]
Iwamuro M (2026). [PMID: 42005579](https://pubmed.ncbi.nlm.nih.gov/42005579/). *Case Rep Gastrointest Med*. [Case Report / Case Series]
AI-curated news mentioning Cronkhite-Canada syndrome
Updated May 12, 2026
A bibliometric analysis highlights the current challenges and opportunities in Cronkhite-Canada syndrome research. The study provides insights into publication trends and research gaps, emphasizing the need for further investigation into this rare condition.
cronkhite canada syndrome a diagnostic challenge and management with vedolizumab